Stock data
| Market cap. | £26.3m |
| Last close | 130.50p |
| High / Low (52 weeks) | 243.0p / 110.0p |
| Stock market listing | AIM |
| Forecast net cash (£m) | 12.3 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | (2.61) | (29.46) | (34.75) |
| Relative * | 2.17 | (23.67) | (28.29) |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (£m) | EBITDA (£m) | PBT (£m) | EPS (p) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2010A | 3.0 | (8.4) | (8.4) | (73.5) | N/A | N/A |
| 2011A | 4.0 | (11.0) | (11.1) | (60.1) | N/A | N/A |
| 2012E | 4.9 | (10.0) | (10.3) | (43.7) | N/A | N/A |
| 2013E | 12.3 | (10.7) | (11.0) | (35.5) | N/A | N/A |
Last updated on 11/05/2012
Latest research
Race against the clock
Update | Pharmaceutical & Healthcare | 11/05/2012
US verdict this year
Update | Pharmaceutical & Healthcare | 10/04/2012
Breathing space
Update | Pharmaceutical & Healthcare | 15/03/2012
Pathway to US approval
Update | Pharmaceutical & Healthcare | 07/09/2011
Angling for US approval
Outlook | Pharmaceutical & Healthcare | 08/08/2011
Widening the angle
Outlook | Pharmaceutical & Healthcare | 11/08/2009
£3.4m interim funding
Update | Pharmaceutical & Healthcare | 29/09/2008
Enrolment starts to rise
Review | Pharmaceutical & Healthcare | 29/07/2008
Pythagoras theorem
Update | Pharmaceutical & Healthcare | 26/03/2008
Building an Aorfix model
Outlook | Pharmaceutical & Healthcare | 17/01/2008
Investment summary
The FDA’s requirement for additional analyses of the existing Aorfix dataset in the PMA process means that the clock on the 180-day review will be restarted once the new data are submitted. It is vital that approval comes before 31 December 2012 for Lombard to receive a £14.2m tranche of funding needed to finance the launch and continue development of the device. If the approval timeline extends further, the company could carry out cost retrenchment or negotiate a new round of funding.
Last updated on 11/05/2012
Industry outlook
Lombard will compete with larger US corporations to achieve further penetration in the $1.1bn global AAA market on the basis of US FDA approval for Aorfix. The 0-90º label claim (above 60º would be unique) and clinical evidence provide a potential competitive edge for Aorfix in the endovascular aneurysm repair-receptive US market.
Last updated on 23/04/2012
Key management
| Simon Hubbert, CEO |
| Ian Ardill , CFO |
Company address
| Lombard Medical House, 4 Trident Park Didcot OX14 7HJ United Kingdom +44 (0) 1235 750 800 View website |
